HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

DPH-067517

structure in first source

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Piperidines: 17
    - DPH-067517: 1
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Quinolines: 146
      - DPH-067517: 1

Experts

1.	Decicco, Carl P: 1 article (04/2004)
2.	Duan, James J-W: 1 article (04/2004)
3.	Feuerstein, Giora Z: 1 article (04/2004)
4.	Liu, Rui-Qin: 1 article (04/2004)
5.	Ogletree, Martin L: 1 article (04/2004)
6.	Schumacher, William A: 1 article (04/2004)
7.	Taub, Rebecca: 1 article (04/2004)
8.	Wang, Hugh: 1 article (04/2004)
9.	Wang, Xinkang: 1 article (04/2004)
10.	Xu, Lin: 1 article (04/2004)

Related Diseases

1.	Ischemia 04/01/2004 - "The salutary effect of DPH-067517 in ischemic brain injury was also observed when the first dose was administrated 60 min after the onset of ischemia. " 04/01/2004 - "DPH-067517 selectively inhibited TACE enzyme activity in vitro (K(i) = 2.8 nM), and effectively suppressed ischemia-induced increase in soluble TNFalpha in brain tissue after systemic administration. "
2.	Brain Injuries (Brain Injury) 04/01/2004 - "The salutary effect of DPH-067517 in ischemic brain injury was also observed when the first dose was administrated 60 min after the onset of ischemia. "
3.	Ischemic Stroke 04/01/2004 - "Using a selective small molecule inhibitor of TACE, DPH-067517, we tested the hypothesis that inhibition of TNFalpha formation might have a salutary effect in ischemic stroke induced by embolic occlusion of the middle cerebral artery (MCAO). "

Related Drugs and Biologics

1.	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
2.	ADAM17 Protein